Joanna Opalinska
About
Joanna Opalinska is a scholar working on Hematology, Molecular Biology and Oncology.
According to data from OpenAlex, Joanna Opalinska has authored 52 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hematology, 32 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in Joanna Opalinska's work include Multiple Myeloma Research and Treatments (28 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and RNA Interference and Gene Delivery (9 papers). Joanna Opalinska is often cited by papers focused on Multiple Myeloma Research and Treatments (28 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and RNA Interference and Gene Delivery (9 papers). Joanna Opalinska collaborates with scholars based in United States, United Kingdom and Canada. Joanna Opalinska's co-authors include Alan M. Gewirtz, Rakesh Popat, Adam D. Cohen, Paul G. Richardson, Suzanne Trudel, Peter M. Voorhees, Axel Hoos, Zangdong He, Nikoletta Lendvai and Edward N. Libby and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Clinical Oncology.
In The Last Decade
Joanna Opalinska
51 papers receiving 1.8k citations
Peers
Joanna Opalinska
Peter Bross United States
Amanda L. Christie United States
Michaël Sébag Canada
Jiro Kikuchi Japan
Douglas W. Sborov United States
David R. Stover United States
Sonia Vallet United States
Audie Rice United States
Christine M. McMahon United States
Dilara McCauley United States
Citations per year, relative to Joanna Opalinska Joanna Opalinska (= 1×)
peers
Peter Bross
Countries citing papers authored by Joanna Opalinska
Since
Specialization
Citations
This map shows the geographic impact of Joanna Opalinska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joanna Opalinska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joanna Opalinska more than expected).
Fields of papers citing papers by Joanna Opalinska
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Joanna Opalinska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joanna Opalinska. The network helps show where Joanna Opalinska may publish in the future.
Co-authorship network of co-authors of Joanna Opalinska
This figure shows the co-authorship network connecting the top 25 collaborators of Joanna Opalinska. A scholar is included among the top collaborators of Joanna Opalinska based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joanna Opalinska. Joanna Opalinska is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mukhopadhyay, Pralay, Joanna Opalinska, Katja Weisel, et al.. (2025). The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development. Blood Cancer Journal. 15(1). 15–15.
2.
Hungria, Vânia, Paweł Robak, Marek Hus, et al.. (2024). Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S242–S242.
3.
Hungria, Vânia, Paweł Robak, Marek Hus, et al.. (2024). Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(16_suppl). 7543–7543.
4.
Robak, Paweł, Marek Hus, Chengcheng Fu, et al.. (2024). MM-557 DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S571–S571.
5.
Hungria, Vânia, Marek Hus, Paweł Robak, et al.. (2024). Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial. Blood. 144(Supplement 1). 3359–3359.
6.
Mateos, María‐Victoria, Paweł Robak, Marek Hus, et al.. (2024). DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(16_suppl). 7503–7503.
7.
Popat, Rakesh, Bradley Augustson, Mercedes Gironella, et al.. (2023). Belantamab Mafodotin in Combination with Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Analysis of DREAMM-6 Trial Arm-a. Blood. 142(Supplement 1). 2010–2010.
8.
Lonial, Sagar, Ajay K. Nooka, Praneetha Thulasi, et al.. (2021). Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer Journal. 11(5). 103–103.
9.
Farooq, Asim V., Simona Degli Esposti, Rakesh Popat, et al.. (2020). Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmology and Therapy. 9(4). 889–911.
10.
Richardson, Paul G., Hans C. Lee, Adam D. Cohen, et al.. (2020). Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer Journal. 10(10). 106–106.
11.
Trudel, Suzanne, Nikoletta Lendvai, Rakesh Popat, et al.. (2019). Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer Journal. 9(4). 37–37.
12.
Aghajanian, Carol, Katherine M. Bell‐McGuinn, Howard A. Burris, et al.. (2018). A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. Investigational New Drugs. 36(6). 1016–1025.
13.
Trudel, Suzanne, Nikoletta Lendvai, Rakesh Popat, et al.. (2018). Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. The Lancet Oncology. 19(12). 1641–1653.
14.
Isufi, Iris, Mahesh Seetharam, Li Zhou, et al.. (2007). Transforming Growth Factor- β Signaling in Normal and Malignant Hematopoiesis. Journal of Interferon & Cytokine Research. 27(7). 543–552.
15.
Opalinska, Joanna. (2007). Nucleic acid drugs in the clinic. Expert Opinion on Drug Discovery. 2(3). 321–333.
16.
Opalinska, Joanna, Anna Kalota, Jyoti Chattopadhyaya, Masad J. Damha, & Alan M. Gewirtz. (2006). Nucleic Acid Therapeutics for Hematologic Malignancies—Theoretical Considerations. Annals of the New York Academy of Sciences. 1082(1). 124–136.
17.
Opalinska, Joanna, Davendra Sohal, Simrit Parmar, et al.. (2006). A High Resolution Epigenomic Map of Myelofibrosis Reveals Multiple Chromosomal Deletions and Amplifications Accompanied by a High Level of Functionally Important Methylation.. Blood. 108(11). 2684–2684.
18.
Opalinska, Joanna & Alan M. Gewirtz. (2005). Rationally Targeted, Conformationally Constrained, Oxetane‐Modified Oligonucleotides Demonstrate Efficient Gene‐Silencing Activity in a Cellular System. Annals of the New York Academy of Sciences. 1058(1). 39–51.
19.
Opalinska, Joanna. (2004). Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules. Nucleic Acids Research. 32(19). 5791–5799.
20.
Busse, Dagmar, F.W. Busch, Frank Bohnenstengel, et al.. (1997). Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism.. Journal of Clinical Oncology. 15(5). 1885–1896.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Peter Bross Breakdown of academic impact, for papers by Amanda L. Christie Breakdown of academic impact, for papers by Michaël Sébag Breakdown of academic impact, for papers by Jiro Kikuchi Breakdown of academic impact, for papers by Douglas W. Sborov Breakdown of academic impact, for papers by David R. Stover Breakdown of academic impact, for papers by Sonia Vallet Breakdown of academic impact, for papers by Audie Rice Breakdown of academic impact, for papers by Christine M. McMahon Breakdown of academic impact, for papers by Dilara McCauley